Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01577745 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT01577745 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 58 participants.
The verdict
NCT01577745, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm, dose-escalation (3+3) study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI0639.
Interventions
- BIOLOGICAL MEDI0639
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01577745
The ClinicalTrials.gov registry entry for NCT01577745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI0639 is the first listed.
NCT01577745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01577745 about?
NCT01577745 is a clinical study titled "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors". This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm, dose-escalation (3+3) study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI0639.
What is the current status of trial NCT01577745?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2012-04. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01577745?
The interventions under investigation include: MEDI0639 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01577745?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.